Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.15
-35.7%
$0.26
$0.12
$2.90
N/AN/A8,454 shs3,200 shs
Biocept, Inc. stock logo
BIOC
Biocept
$0.97
$0.32
$27.00
$1.14M0.69764,067 shs751,400 shs
PRENW
Prenetics Global
$0.01
+8.1%
$0.01
$0.01
$0.02
N/AN/A79,318 shs116 shs
SQLLW
SeqLL
$0.01
$0.01
$0.00
$0.11
N/AN/A9,750 shsN/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
-3.31%-25.51%-33.03%-51.82%-59.44%
Biocept, Inc. stock logo
BIOC
Biocept
0.00%0.00%0.00%0.00%0.00%
PRENW
Prenetics Global
-14.00%-14.00%-20.37%-12.24%+14.67%
SQLLW
SeqLL
0.00%0.00%0.00%+228.50%+238.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/AN/AN/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00
N/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
0.00
N/AN/AN/A
PRENW
Prenetics Global
0.00
N/AN/AN/A
SQLLW
SeqLL
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$9.36MN/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
$25.86M0.00N/AN/A$15.60 per share0.00
PRENW
Prenetics Global
$25.56MN/AN/AN/AN/AN/A
SQLLW
SeqLL
$1.18KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/A
PRENW
Prenetics Global
N/AN/A0.00N/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
2.88
1.81
1.70
PRENW
Prenetics Global
N/AN/AN/A
SQLLW
SeqLL
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
Biocept, Inc. stock logo
BIOC
Biocept
N/A
PRENW
Prenetics Global
N/A
SQLLW
SeqLL
N/A

Insider Ownership

CompanyInsider Ownership
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
Biocept, Inc. stock logo
BIOC
Biocept
1.61%
PRENW
Prenetics Global
N/A
SQLLW
SeqLL
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
10N/AN/ANot Optionable
Biocept, Inc. stock logo
BIOC
Biocept
502.63 million2.58 millionNot Optionable
PRENW
Prenetics Global
1N/AN/ANot Optionable
SQLLW
SeqLL
7N/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAFW

$0.15 -0.08 (-35.68%)
As of 04/29/2025 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Biocept stock logo

Biocept NASDAQ:BIOC

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Prenetics Global NASDAQ:PRENW

$0.0093 +0.00 (+8.14%)
As of 03:52 PM Eastern

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

SeqLL NASDAQ:SQLLW

$0.0066 0.00 (0.00%)
As of 04/29/2025

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.